Soluble Adhesion Molecules in the HIT Syndrome: Pathophysiologic Role and Therapeutic Modulation

Heparin-induced thrombocytopenia pathophysiology is now known to be a complex process that involves platelets, vascular endothelium, and leukocytes/lymphocytes. The activation products from these sites also contribute to the activation of coagulation and fibrinolytic deficit. While many of the markers of hemostatic activation processes have been found to be increased during the acute phase of heparin-induced thrombocytopenia syndromes, the circulating levels of soluble adhesion molecules such as the P, E, and L selectins, and intracellular and vascular cell adhesion molecules have not been reported. Since the pathophysiology of heparin-induced thrombocytopenia involves the activation of platelets, endothelium, and leukocytes, it is expected that the activation products related to these hemostatic systems including soluble selectins and cellular adhesion molecules will also be increased in circulating blood. These alterations may also provide an index of the pathophysiologic process. With the availability of highly sensitive enzyme-linked immunosorbent assays for soluble P, E, and L selectins, intracellular and vascular cell adhesion molecules, it is now possible to measure these adhesion molecules in biological fluids. This study reports on the circulating levels of various adhesion molecules in patients with heparin-induced thrombocytopenia and their modulation after therapeutic interventions by the use of direct thrombin inhibitors. With the availability of recombinant hirudin, it is now possible to treat these patients with alternate antithrombin agents. However, the immunoactivation of platelets and other cells as shown here indicates the possible need for additional adjunct therapeutic approaches to suppress their participation in the thrombotic process. The reported increase in the circulating levels of the soluble adhesion molecules during the heparin-induced thrombocytopenia and heparin-induced thrombocytopenia with thrombosis syndrome suggests that the antiheparin platelet factor 4 antibody is capable of modulating their regulation. The prognostic role of these mediators in the management of heparin-induced thrombocytopenia syndrome warrants further investigation.

[1]  D. Hoppensteadt,et al.  Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. , 1998, Clinical chemistry.

[2]  E. Topol,et al.  Heparin-induced thrombocytopenia. , 1998, Journal of the American College of Cardiology.

[3]  J. Walenga,et al.  Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. , 1998, The Medical clinics of North America.

[4]  K. Murphy,et al.  Heparin-induced thrombocytopenia and thrombosis syndrome , 1997 .

[5]  J. Amiral,et al.  Pathogenicity of IgA and/or IgM antibodies to heparin–PF4 complexes in patients with heparin‐induced thrombocytopenia , 1996, British journal of haematology.

[6]  Pablo Engel,et al.  The selecting: vascular adhesion molecules , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  Y. Koga,et al.  Soluble form of P-selectin in patients with acute myocardial infarction. , 1994, Coronary artery disease.

[8]  Y. Ikeda,et al.  Soluble P‐selectin is present in normal circulation and its plasma level is elevated in patients with thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome , 1993, British journal of haematology.

[9]  P. Selby,et al.  Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. , 1993, British Journal of Cancer.

[10]  J. Kelton,et al.  Heparin‐induced thrombocytopenia and thrombosis: clinical and laboratory studies , 1993, British journal of haematology.

[11]  G. Hunder,et al.  Serum ELAM-1 is increased in vasculitis, scleroderma, and systemic lupus erythematosus. , 1993, The Journal of rheumatology.

[12]  T. V. Gopal,et al.  Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock. , 1993, Journal of immunology.

[13]  S. J. Cashman,et al.  Soluble Forms of Vascular Adhesion Molecules, E‐Selectin, ICAM‐1, and VCAM‐1: Pathological Significance , 1992, Annals of the New York Academy of Sciences.

[14]  D. Silver,et al.  The heparin-induced thrombocytopenia syndrome: an update. , 1987, Surgery.

[15]  S. Tannenbaum,et al.  Immune endothelial-cell injury in heparin-associated thrombocytopenia. , 1987, The New England journal of medicine.

[16]  D. Hoppensteadt,et al.  Molecular Markers of Hemostatic Activation in Atherosclerosis: A New Concept in Diagnostic Profiling of Endogenous Pathophysiologic Transition , 1986, Seminars in thrombosis and hemostasis.

[17]  J. Fareed,et al.  Molecular Markers of Hemostatic Activation: Future Perspectives , 1984, Seminars in thrombosis and hemostasis.

[18]  J. Fareed,et al.  Molecular Markers of Platelet Activation , 1984, Seminars in thrombosis and hemostasis.

[19]  J. Amiral,et al.  Application of enzyme immunoassays to coagulation testing. , 1984, Clinical chemistry.

[20]  R. Cipolle,et al.  Heparin‐induced thrombocytopenia in patients with cerebrovascular ischemic disease , 1984, Neurology.

[21]  B. Chong,et al.  HEPARIN-INDUCED THROMBOCYTOPENIA: ASSOCIATION OF THROMBOTIC COMPLICATIONS WITH HEPARIN-DEPENDENT IgG ANTIBODY THAT INDUCES THROMBOXANE SYNTHESIS AND PLATELET AGGREGATION , 1982, The Lancet.

[22]  W. Garrisi,et al.  Heparin-induced thrombocytopenia and thrombosis syndrome. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[23]  B. Chong,et al.  Heparin-induced thrombocytopenia: association of thrombotic complications with heparin-dependent IgG antibody that induces thromboxane synthesis in platelet aggregation. , 1982, Lancet.